A two-stage patient enrichment adaptive design in phase II oncology trials

Contemporary Clinical Trials

Volumn 37, Issue 1, 2014, Pages 148-154

  Song, James X ^a  

^a NONE   (United States)

Author keywords

Adaptive design; Oncology; Phase II trials; Predictive marker

Indexed keywords

ALPHA FETOPROTEIN; ANTIBODY; BIOLOGICAL MARKER; EXPERIMENTAL ANTIBODY; SORAFENIB; UNCLASSIFIED DRUG;

ARTICLE; BAYES THEOREM; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL EVALUATION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERIM ANALYSIS; LIVER CELL CARCINOMA; OVERALL SURVIVAL; PATIENT ENRICHMENT ADAPTIVE DESIGN; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PROBABILITY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION; STUDY DESIGN; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY;

ADAPTIVE DESIGN; ONCOLOGY; PHASE II TRIALS; PREDICTIVE MARKER;

BAYES THEOREM; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; MODELS, STATISTICAL; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84891313102     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2013.12.001     Document Type: Article

References (19)

1. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with braf v600E mutation. N Engl J Med 2011, 364:2507-2516.
2. Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products, Draft Guidance, FDA CDER, CBER December 2012.
3. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics, Draft Guidance, FDA CDER, CBER February 2010.
4. Wang S.J., O'Neill R.T., Hung H.M.J. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 2007, 6:227-244.
5. Simes R.J. An improved bonferroni procedure for multiple tests of significance. Biometrika 1986, 73:751-754.
6. Jennison C., Trunbull B.W. Adaptive seamless designs: selection and prospective testing of hypotheses. J Biopharm Stat 2007, 17:1135-1161.
7. Brannath W., Zuber E., Branson M., Bretz F., Gallo P., Posch M., et al. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Stat Med 2009, 28:1445-1463.
8. Zhao Y.D., Dmitrienko A., Tamura R. Design and analysis considerations in clinical trials with a sensitive subpopulation. Stat Biopharm Res 2010, 2:72-83.
9. Li D., Mehrotra D.V. An efficient method for accommodating potentially underpowered primary endpoints. Stat Med 2008, 27:5377-5391.
10. Alosh M., Huque M. A flexible strategy for testing subgroups and overall population. Stat Med 2009, 28:3-23.
11. Jiang W.Y., Freidlin B., Simon R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 2007, 99:1036-1043.
12. Freidlin B., Jiang W., Simon R. The cross-validated adaptive signature design. Clin Cancer Res 2010, 16:691-698.
13. Huang X.L., Ning J., Li Y., Estey E., Issa J.P., Berry D.A. Using short-term response information to facilitate adaptive randomization for survival clinical trials. Stat Med 2009, 28:1680-1689.
14. Gan H.K., Grothey A., Pond G.R., Moore M.J., Siu L.L., Sargent D. Randomized phase II trials: inevitable or inadvisable?. J Clin Oncol 2010, 28:2641-2647.
15. Cui L., Hung H.M.J., Wang S.J. Modification of sample size in group sequential clinical trials. Biometrics 1999, 55:853-857.
16. Yau T., Yao T.J., Chan P., Wong H., Pang R., Fan S.T., et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist 2011, 16:1270-1279.
17. Zohar S., Baldi I., Forni G., Merletti F., Masucci G., Gregori D. Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas. Pharm Stat 2010, 10:218-226.
18. Yin G., Yuan Y. Bayesian model averaging continual reassessment method in phase I clinical trials. J Am Stat Assoc 2009, 104:954-968.
19. Spiegelhalter D., Best N., Carlin B., Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B 2002, 64:583-639.